Here are 10 of UBS' top stock picks for 2024
It’s that time of year: 2024 forecasts are all upon us. If you’re interested in stocks, you’ll want to have a look at this one from UBS. Each of Its analysts offered his/her top stock pick for next year. And out of that, UBS formed a list of the 24 “most compelling” stock ideas for the year ahead,…#ubs #gavinparsons #boeing #chevron #cvx #cocacola #coke #petergrom #etr #merck (Source: Reuters: Health)
Source: Reuters: Health - December 26, 2023 Category: Consumer Health News Source Type: news
Could Ginkgo Bioworks Stock Help You Become a Millionaire?
A big part of the allure of investing in small and mid-cap stocks is their potential to be worth much more in the future. After all, it's a lot more probable that a company that's only worth a few billion dollars will grow its business enough to double in value than it is for a company that's…#ginkgobioworks #ginkgo #pfizer #biogen #merck #novonordisk #bayer #davidjagielski #motleyfool (Source: Reuters: Health)
Source: Reuters: Health - December 26, 2023 Category: Consumer Health News Source Type: news
Merck: One Of The Best
(Source: Reuters: Health)
Source: Reuters: Health - December 25, 2023 Category: Consumer Health News Source Type: news
January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump
These January stocks could see a boost in the new year As the world bids adieu to one year and eagerly ushers in the next, the financial landscape comes alive with whispers of a phenomenon known as the January Effect. It’s a time when astute investors set their sights on uncovering hidden…#lowes #diy #pro #prorewards #mvp #crm #merck #keytruda #cocacola #cocacolas (Source: Reuters: Health)
Source: Reuters: Health - December 24, 2023 Category: Consumer Health News Source Type: news
Dow Jones Holds Up Despite Nike Sell-Off; Inflation Cools, But Chinese Stocks Plunge On Clampdown News
The Dow Jones Industrial Average held a modest gain along with other major stock indexes in afternoon trading Friday despite an earnings sell-off for Dow component Nike (NKE). Nike stock plunged more than 10% after the company missed on revenue for the second straight quarter and also cut its…#dow #nke #nike #amgen #amgn #walmart #wmt #merck #mck #intel (Source: Reuters: Health)
Source: Reuters: Health - December 23, 2023 Category: Consumer Health News Source Type: news
FDA Rejects Drug for Chronic Cough
(MedPage Today) -- The FDA declined to approve oral gefapixant for treating chronic cough, Merck announced on Wednesday.
In its complete response letter, "the FDA concluded that Merck's application did not meet substantial evidence of effectiveness... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - December 21, 2023 Category: Allergy & Immunology Source Type: news
US FDA Declines to Approve Merck's Chronic Cough Drug US FDA Declines to Approve Merck's Chronic Cough Drug
The U.S. Food and Drug Administration (FDA) declined to approve Merck ' s drug for chronic cough, the company said on Wednesday, marking the second rejection in less than two...Reuters Health Information (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - December 20, 2023 Category: Primary Care Tags: Family Medicine/Primary Care Source Type: news
Merck Provides U.S. Regulatory Update on Gefapixant
RAHWAY, N.J.--(BUSINESS WIRE) December 20, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 20, 2023 Category: Drugs & Pharmacology Source Type: news
Merck, Astellas and Pfizer bring down the house with Keytruda-Padcev FDA nod in bladder cancer
The combination therapy was hailed with a standing ovation in October at the European Society for Medical Oncology (ESMO) conference in Madrid. Less than two months later, the FDA has added its acclaim—blessing it five months ahead of its PDUFA date. On Friday the U.S. regulator signed off on…#fda #pfizerspadcev #merck #keytruda #seagen #ahsanarozullah #rogerdansey #pfizer #padcev #pd1 (Source: Reuters: Health)
Source: Reuters: Health - December 19, 2023 Category: Consumer Health News Source Type: news
Jim Cramer explains how FTC chair Lina Khan is hurting investor portfolios
CNBC's Jim Cramer outlined the ways that Federal Trade Commission chair Lina Khan has attempted to stop mergers and acquisitions from going through, hurting stock portfolios in the process. "Khan's FTC has deterred many a potential merger, and that's kept stock valuations much lower than they…#jimcramer #linakhan #ftc #nipponsteelussteel #nipponsteel #ussteel #riteaid #amazon #merck #bristolmeyers (Source: Reuters: Health)
Source: Reuters: Health - December 18, 2023 Category: Consumer Health News Source Type: news
Landmark Melanoma Vaccine Could Be Available in Just 2 Years
Moderna CEO Stephane Bancel told AFP his company's experimental vaccine against melanoma could be available in as little as two years, in what would amount to a landmark step against the most serious form of skin cancer. Globally there were an estimated 325,000 new melanoma cases and 57 ,000…#moderna #stephanebancel #afp #bancel #rna #merck #keytruda #mrna4157 #massachusetts #fda (Source: Reuters: Health)
Source: Reuters: Health - December 18, 2023 Category: Consumer Health News Source Type: news
Big pharma can ’t get enough of one class of cancer drugs
A world, dealmaking is in a rut. A combination of higher interest rates, geopolitical tensions and economic uncertainty has put a hold on joint ventures, mergers and acquisitions. One exception is targets with in their name. Another, less obvious one, involves a less catchy initialism: s. Makers…#seagen #nurixtherapeutics #amgen #astrazeneca #merck #daiichisankyo #bristolmyerssquibb #susangalbraith #trodelvy #gileadsciences (Source: Reuters: Health)
Source: Reuters: Health - December 18, 2023 Category: Consumer Health News Source Type: news
Melanoma vaccine may improve survival, study shows
A new melanoma vaccine has shown its mettle in battling the deadly skin cancer in a new trial. People with advanced melanomas who received the vaccine plus Merck's cancer drug Keytruda were 49% less likely to die or have their cancer return after three years than those who were given only…#merck #keytruda #modernainc (Source: Reuters: Health)
Source: Reuters: Health - December 16, 2023 Category: Consumer Health News Source Type: news
FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer
On December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, Merck) for patients with locally advanced or metastatic urothelial cancer (la/mUC). FDA previously granted accelerated approval to this (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 15, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
New Melanoma Treatment Vaccine Shows Promise in Trial
FRIDAY, Dec. 15, 2023 -- A new melanoma vaccine has shown its mettle in battling the deadly skin cancer in a new trial.
People with advanced melanomas who received the vaccine plus Merck ' s cancer drug Keytruda were 49% less likely to die or have... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 15, 2023 Category: General Medicine Source Type: news
